EGFR and breast carcinoma: FABP5 silencing has been shown to decrease cell proliferation and lead to cell cycle arrest in gastric cancer.27 In breast cancer, FABP5 activates VEGF and up-regulates EGFR expression, in turn, increasing PPAR to promote cancer progression28.